Anti-Mouse CD70 (Clone TAN1-7) – Purified in vivo PLATINUM™ Functional Grade
Anti-Mouse CD70 (Clone TAN1-7) – Purified in vivo PLATINUM™ Functional Grade
Product No.: I-2025
- -
- -
Clone TAN1-7 Target CD70 Formats AvailableView All Product Type Monoclonal Antibody Alternate Names CD27 Ligand, TNFSF7, Tumor Necrosis Factor Ligand 8A, CD27L, CD70 Antigen, CD27LG, Surface Antigen CD70, CD70 Molecule, Ki-24 Antigen; CD70 Antigen; TNLG8A Isotype Mouse IgG2a k Applications B , ELISA , FA , FC , IF , in vivo |
- -
- -
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Mouse Recommended Isotype Controls Recommended Dilution Buffer Immunogen Recombinant mouse CD70 (extracellular domain, aa residues 41-195) Product Concentration ≥ 5.0 mg/ml Endotoxin Level ≤ 0.5 EU/mg as determined by the LAL method Purity ≥98% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM<sup>TM</sup> antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2893831 Applications and Recommended Usage? Quality Tested by Leinco FC ELISA Additional Applications Reported In Literature ? B IF Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone TAN1-7 monoclonal antibody recognizes a direct epitope on mouse CD70 and capable of blocking the CD70-CD27 interaction involved in B and T cell activation.
Background CD70 antibody, TAN1-7, recognizes CD70, a type II membrane protein and member of the TNF family. CD70 is the ligand for the T cell costimulatory receptor CD27 (also known as TNFRSF27)1 and is expressed on activated T cells, B cells, and dendritic cells (DCs)1,2. Ligation of CD27 on T cells with CD70 on DCs provides costimulatory signals and promotes CD4 and CD8 T cell activation3, differentiation4, and survival5,6. CD70 also regulates B cell activation and antibody production7 and enhances natural killer (NK) cell survival and function8. CD70 is constitutively expressed in several hematological and solid tumors and increases the proliferation and survival of tumor cells and regulatory T cells (Tregs), suggesting it may be an effective therapeutic target9-13. Increased levels of CD70 are also associated with autoimmune disorders, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)14,15. Antigen Distribution CD70 is expressed on activated T cells, B cells, and dendritic cells. PubMed NCBI Gene Bank ID UniProt.org Research Area Costimulatory Molecules . Immunology References & Citations1. R. A. van Lier., et al. (1997) J. Immunol. 159(10):4959-65 2. R. A. van Lier. et al. (2003) J. Immunol. 170(1):33-40 3. Hintzen, R. Q. et al. (1995) J. Immunol. 154, 2612–2623 4. Soares, H. et al. (2007) J. Exp. Med. 204, 1095–1106 5. Hendriks, J. et al. (2000) Nat. Immunol.1, 433–440 6. Hendriks, J., Xiao, Y. & Borst, J. (2003) J. Exp. Med.198, 1369–1380 7. van Oers MH., et al. (2004) J Immunol. 15;173(6):3901-8. 8. Ochsenbein AF., et al. (2017) 20;130(3):297-309 9. Ansell SM., et al. (2007) Blood. 110:2537–2544 10. Doronina SO., et al. (2006) Cancer Res. 66:2328–2337 11. Weller M., et al. (2002) Cancer Res. 62:2592–2599 12. Held-Feindt, J. & R. Mentlein. (2002) Int. J. Cancer 98:352 13. Chiodi F., et al. (2005) Exp Hematol. 33:1500–1507 14. Han, B. K. et al. (2005) Lupus. 14, 598–606 15. Park, J. K. et al. (2014) Rheumatology. 53, 1896–1900 Technical ProtocolsCertificate of Analysis |
Formats Available
- -
- -
Products are for research use only. Not for use in diagnostic or therapeutic procedures.